Intellia Therapeutics (NTLA) Accumulated Expenses (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Accumulated Expenses of $9.3 million for Q1 2026, down 77.15% year-over-year from $40.8 million in Q1 2025, and down 81.3% quarter-over-quarter from $49.9 million in Q4 2025.
Intellia Therapeutics (NTLA) Accumulated Expenses (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Accumulated Expenses for 12 consecutive years, with $9.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses fell 77.15% year-over-year to $9.3 million; the TTM figure through Mar 2026 stood at $9.3 million (down 77.15% YoY), while the FY2025 annual figure was $49.9 million, down 9.92% from the prior year.
- Accumulated Expenses fell to $9.3 million in Q1 2026 per NTLA's latest filing, from $49.9 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $67.0 million in Q4 2023 and bottomed at $9.3 million in Q1 2026.
- Historically, Accumulated Expenses has averaged $31.5 million across 5 years, with a median of $21.8 million in 2022.
- Annual changes were most pronounced in 2023 — Accumulated Expenses surged 301.99% — and 2026, when it plunged 77.15%.
- Intellia Therapeutics' Accumulated Expenses stood at $21.8 million in 2022, then surged by 207.73% to $67.0 million in 2023, then fell by 17.4% to $55.4 million in 2024, then retreated by 9.92% to $49.9 million in 2025, then tumbled by 81.3% to $9.3 million in 2026.
- Business Quant data shows NTLA's Accumulated Expenses at $9.3 million in Q1 2026, $49.9 million in Q4 2025, and $16.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.33 Mn |
| Mar 31, 2026 | 9.32 Mn |
| Dec 31, 2025 | 49.86 Mn |
| Sep 30, 2025 | 16.83 Mn |
| Jun 30, 2025 | 41.55 Mn |
| Mar 31, 2025 | 40.81 Mn |
| Dec 31, 2024 | 55.36 Mn |
| Sep 30, 2024 | 51.21 Mn |
| Jun 30, 2024 | 14.90 Mn |
| Mar 31, 2024 | 10.39 Mn |
| Dec 31, 2023 | 67.02 Mn |
| Sep 30, 2023 | 21.01 Mn |
| Jun 30, 2023 | 49.53 Mn |
| Mar 31, 2023 | 44.82 Mn |
| Dec 31, 2022 | 21.78 Mn |
| Sep 30, 2022 | 17.92 Mn |
| Jun 30, 2022 | 12.88 Mn |
| Mar 31, 2022 | 11.15 Mn |
| Dec 31, 2021 | 43.31 Mn |
| Sep 30, 2021 | 11.83 Mn |